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Abstract
Purpose of Review The novel Coronavirus (2019-nCoV, COVID-19) is historically one of the most severe acute respiratory
syndromes and pandemics to affect the globe in the twenty-first century. Originating in Wuhan, the virus rapidly spread and
impacted subsets of populations with initial unclear risk factors contributing to worsening morbidity and mortality. Patients with
diagnosis of cancer and undergoing treatment further represent a population at risk for worsening cardiopulmonary outcomes. This
review explores specific risk factors, diagnoses, and treatment options that impact cardio-oncologic patients with COVID-19.
Recent Findings Multiple studies globally, including Italy, China, and the USA, have documented severe outcomes. Cancer
patients are at increased risk of cardiac injury which itself is a risk factor for mortality. Additionally, elderly cancer patients
undergoing recent anti-cancer treatment may be at greater risk for sustaining worse outcomes, although data remains suboptimal
in this population. Major gaps remain regarding risk associated with type of cancer and type of anti-cancer treatment, as well as
the layered risk of cardiovascular disease and cancer. Immunomodulatory therapies used to treat cytokine release syndrome
secondary to anti-cancer therapies, as well as other agents being traditionally used to treat cardiovascular and cancer disease
states, are being investigated for treatment of COVID-19.
Summary Hypertension, cardiovascular disease, diabetes, and cancer have been associated with more severe COVID-19 infec-
tion and worse outcomes. Patients undergoing anti-cancer therapy or those who have suffered from coronavirus infection may
develop long-standing changes, not limited to pulmonary fibrosis, hyperlipidemia, and worsening atherosclerosis. Those under-
going anti-cancer therapy are at theoretically increased susceptibility for infection, with type of cancer not necessarily dictating
outcome. A review of the literature of patients with cardiovascular and/or cancer disease is presented, as well as proposed
strategies to attenuate risk regarding treatment, management, and surveillance in this vulnerable population.
Keywords COVID-19 . Cardio-oncology . Cancer . Cardiovascular disease
Introduction
The spread of novel Coronavirus (2019-nCoV, COVID-19)
shook the world with its highly virulent transmissibility, man-
ifesting largely as a severe acute respiratory syndrome, with
more than 4.3 million people confirmed to be infected—with
approximately 1.3 million cases in the USA—and over
294,000 deaths worldwide at the time of this writing [1].
Originating in China, the COVID-19 epidemic has surpassed
its predecessors in the number of hospitalizations and inten-
sive care unit admissions required to handle an infectious pro-
cess within a short period of time and of such grand scale [2].
The early SARS epidemic that emerged in 2002 similarly
involved human-to-human transmission, with animal vectors
linked to outbreaks and confirmed in laboratory isolates [3].
Initially described as pneumonia of unknown origin, COVID-
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19 is believed to be linked to bats based on its genomic sim-
ilarity to known bat coronavirus BatCoV RaTG13 [4].
Though most coronaviruses are mild, two beta-coronaviruses,
severe acute respiratory syndrome (SARS-CoV) and Middle
East Respiratory Syndrome Coronavirus (MERS-CoV), also
took place within the last two decades [5]. These two unique
predecessors preceded the pandemic that began in China in
2019. The virus, originating in Wuhan, Hubei province,
China, in late December, resulted in nearly 96,000 cases ini-
tially and is now considered a worldwide pandemic [6].
Routes of transmission of the virus have been documented
to include respiratory droplets, contact, fomites, and fecal-oral
transmission [7, 8]. The most common symptoms at onset of
illness include fever, cough, myalgia, and fatigue, with rare
complaints of sputum production, headache, hemoptysis, loss
of taste and/or smell, and diarrhea. In addition to clinical char-
acteristics, patients showcased ground-glass opacities on chest
computed tomography scans. However, more than half of the
patients in early studies notably developed dyspnea that cor-
related with patchy infiltrates on chest radiographs. The mean
duration of symptomswas roughly 8 days, with progression to
acute respiratory distress syndrome (ARDS) occurring be-
tween days 8 and 14 [9]. Patients receiving mechanical venti-
lation in the Wuhan Cohort typically required ICU admission
of up to 1–2 weeks following symptom development which
foreshadowed the scale of the pandemic and mirrored data
obtained from the MERS epidemic in 2015 [10, 11].
Epidemiology of COVID-19 and Risk Factors
for Severity of Illness
Epidemiological data from China confirmed the median age of
the patients impacted by the disease to be 59 years, with disease
distribution disproportionately impacting males [12]. The data
further hypothesized that children might be less likely to become
infected, or if infected, demonstrated far milder symptoms. Italy
documented nearly 22,512 cases by March of 2020, with the
largest proportion of cases and fatalities impacting males greater
than 60 years of age [13]. In the Lombardy study, 68%of patients
had at least one existing comorbidity, with hypertension being
most frequently cited. Other predisposing factors included car-
diovascular disease and hypercholesterolemia. A rare subset had
pre-existing lung disease, manifesting as chronic obstructive pul-
monary disease. Roughly 11% of the Lombardy patients were
managed with non-invasive ventilatory support [14]. The need
for invasive ventilatory support varied across regions of the
world, and some of the Wuhan cohort were directly transitioned
to extracorporeal membrane oxygenation (ECMO) for resuscita-
tion purposes [10].
Underlying risk factors, such as hypertension, diabetes,
cardiovascular disease, and immunosuppression, have been
explored as prognosticators regarding clinical outcomes of
COVID-19 infections in hospitalized patients [15•].
However, the impact of the pandemic in patients with a history
of cancer and pre-existing and/or cancer treatment–associated
cardiovascular disease—the cardio-oncology patient—is un-
known. Theoretically, this population is likely at higher risk of
morbidity and mortality from COVID-19 infection, and has
unique healthcare needs that put them at higher risk at expo-
sure from community and healthcare-related transmission.
Examples of these risks include needing ongoing cancer treat-
ments in the outpatient and inpatient setting, as well as
imaging-related procedures and operations for cancer-related
staging and treatments. If these patients also have pre-existing
cardiovascular disease and/or acquired cardiotoxicity during
and after treatments, they also warrant additional evaluation.
Finally, there appears to be a strong correlation with worse
outcomes in hospitalized COVID-19 patients in cardiovascu-
lar and/or cancer-related comorbidities, which will be
reviewed below.
Cardiovascular Disease and COVID-19
Multiple retrospective analyses including those from China, the
USA, and Italy have shown that there is high cardiovascular
disease (CVD) prevalence in patients that develop COVID-19
and particularly those that have more severe disease and worse
outcomes. The mechanism by which cardiovascular patients
have a higher risk of contracting COVID-19 and developing
more severe disease is unknown, but potentially may be due to
poor cardiovascular reserve, a greater associated age with the
cardiovascular conditions, and dysregulated immunity and
existing inflammation from their underlying diseases such as
hypertension and diabetes [16]. An observational database of
the Surgical Outcomes Collaborative registry, which comprised
of 8910 hospitalized COVID-19 patients from 169 hospitals in
Asia, Europe, and North America, found that an age greater than
65, and diagnosis of history coronary artery disease, heart failure,
and/or cardiac arrhythmias were independently associated with
increased risk of in-hospital death, with 5.8% (n = 515) of this
cohort dying in the hospital [17]. Further studies analyzing risk
factors and associated clinical outcomes by geography are further
described below.
China
Ameta-analysis of 6 Chinese studies evaluating 1527 affected
patients showed that the most prevalent cardiovascular meta-
bolic comorbidities included hypertension (17.1%), cardiac
and/or cerebrovascular disease (16.4%), and diabetes (9.7%).
Most importantly, patients with hypertension and cardiac and/
or cerebrovascular disease significantly accounted for more
ICU cases compared with non-ICU cases with prevalence of
28.8% (RR 2.03) for hypertension, and 16.7% (RR 3.30) for
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cardiac and/or cerebrovascular disease [18]. Data from the
World Health Organization and Chinese Center for Disease
Control and Prevention confirm that patients with comorbid-
ities have a higher case fatality rate (CFR) than those without
comorbidities [19, 20]. Of the 55,924 laboratory-confirmed
cases in China, there was a 3.8% CFR and higher rates were
seen with those with CVD (13.2%), diabetes (9.2%), and hy-
pertension (8.4%) [19•]. A cohort study of 201 patients from
Wuhan Jinyintan Hospital showed that hypertension was sig-
nificantly associated with patients progressing to Acute
Respiratory Distress Syndrome (ARDS) (27.4% vs. 13.7%;
p = 0.02) and later death (36.4% vs. 17.5%; p = 0.05) [21].
Italy
As of March 17, 2020, the CFR in Italy is 7.2%. from a
total of 22,512 cases of which a detailed chart review of
a subsample of 355 deceased patients found high under-
lying disease prevalence of ischemic heart disease
(30%), diabetes (35.5%), atrial fibrillation (24.5%), and
cancer (20.3%) [22]. A case series of patients with
COVID-19 in the ICUs in the Lombardy region demon-
strated that hypertension was the most common comor-
bidity (49%) and cardiovascular disease (21%) was the
second. Furthermore, there was a statistically significant
higher prevalence of hypertension among patients who
died compared with those who were discharged from
the ICU (63% vs. 40%; p < 0.001) [14].
USA
While epidemiologic data in the USA remains dynamic with
limited studies to date in major urban centers, a report of 167
confirmed cases linked to a long-term facility in Washington
State also conferred similar findings showing high underlying
disease prevalence with hypertension (44.3%), cardiac disease
(40.7%), and diabetes (22.8%) [23]. A large New York study
examined a total of 5700 patients, with median age being
63 years age. The New York cohort found hypertension in
56.6% patients, obesity in 41.7% patients, and diabetes in
33.8% of patients. Of the patients who died, those with diabe-
tes were more likely to have been mechanically ventilated or
be hospitalized in the ICU [15•]. Another case series of 393
patients admitted to New York hospitals found that 50.1% of
patients had hypertension and 21% had cardiovascular disease
[24]. Not all studies detailed specifics of what defined cardiac
disease; therefore, it is difficult to delineate COVID-19 direct
associations with coronary artery disease, cardiomyopathy, or
heart failure from a large sample size standpoint. However, a
case series from Seattle, Washington did state that 42.9% of
the 21 critically ill patients with COVID-19 had underlying
congestive heart failure [25].
Myocardial Injury and COVID-19
In addition to underlying CVD being a risk factor for
contracting COVID-19, patients that develop acute myocardi-
al injury have worse outcomes, even in those without baseline
cardiovascular dysfunction [25–28]. Acute myocardial injury
can be categorized in three varieties: elevated troponin levels
above the 99th percentile upper reference limit, development
of new or worsening heart failure, and myocarditis. Several
studies from China found that elevated troponin levels were
significantly associated with higher mortality [26–28]. A case
series of 187 patients at the Seventh Hospital of Wuhan City,
China, found that patients with elevated troponin T (TnT)
levels had a significantly higher mortality rate to those with
normal TnT levels (59.6% vs. 8.9%; p < 0.001). Patients with
underlying CVD including those with underlying hyperten-
sion, coronary heart disease, and cardiomyopathy were more
likely to have elevated TnT levels during their hospital course
[26]. Lipid metabolism is also observed to be dysregulated in
patients with SARS-CoV infection. Serum concentrations of
f r ee fa t ty ac ids , ly sophospha t idy l cho l ine , and
phosphatidylglycerol remained elevated and contributed to
chronic cardiovascular damage post infection in patients with
SARS-CoV [29]. Long-term cardiovascular and atheroscle-
rotic changes in patients who suffer from COVID-19 have
not been documented yet given the recent nature of this
pandemic.
A case series of 21 critically ill COVID-19 patients from
Seattle also found that one-third of their patients developed
new cardiomyopathy with cardiogenic shock in the absence of
prior systolic dysfunction during the progression of their ill-
ness [25]. It is unclear if these patients that developed cardio-
myopathy truly had myocarditis or had underlying CVD that
predisposed them to this clinical course. However, COVID-19
has been shown to directly cause myocarditis in otherwise
healthy individuals in several case reports [30, 31]. Thus,
COVID-19 demonstrates various patterns of myocardial inju-
ry, with higher mortality risk being associated with elevated
troponin levels.
In addition, in the cardio-oncology population, elevated
cardiac biomarkers can pose an additional layer of complexity
and challenge when dealing with management. Abnormal el-
evations of troponin and BNP biomarkers can be indicative of
cardiotoxicity from cancer physiology or from the treatments
themselves [32]. Some elevations may be non-specific and are
reflective of subclinical cardiotoxicity in patients receiving
anthracyclines and/or anti-HER2 agents in which stable pa-
tients can be medically managed [33, 34]. However, some
patients receiving other agents such as certain tyrosine kinase
inhibitors with prothrombotic risk (i.e., ponatinib) or
fluoropyridines (i.e., 5-fluorouracil) may suffer cardiotoxicity
in the form of coronary ischemia/vasospasm, which may war-
rant more invasive diagnostic/treatment strategies [35–37].
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Elevated cardiac biomarkers have also been associated with
worse outcomes and or cardiac hemodynamic instability, in-
cluding cytokine release syndrome from chimeric antigen
therapy (CAR-T), heart failure from proteasome inhibitor
use (i.e., carfilzomib), or myocarditis from immune check-
point inhibitor therapy [38–41]. Some of these disease pro-
cesses may confound treatment of a cancer patient also
afflicted with COVID-19, and thus, multidisciplinary assess-
ment, particularly by a cardio-oncologist, may be essential to
provide optimal care in this high-risk population.
Cancer and COVID-19
Cancer patients have shown to be at higher risk for contracting
the virus likely from their immune dysregulation in setting of
their malignancy and various treatments and remain at high
risk for sustaining severe outcomes [19, 42]. Per the WHO
Joint Mission Report, the CFR for cancer patients (7.6%) was
higher than the overall CFR for 55,924 COVID-19 patients in
China [19•]. Reports from Italy and Washington also support
that cancer patients had similar findings [14, 22, 23].
However, the specific type of cancer was neither reported in
these studies nor linked to specific outcome. Several studies
have indicated that cancer patients trend toward having more
severe disease. A case series of patients admitted to NewYork
hospitals identified that 5.9% patients had cancer and 43% of
these patients required invasive ventilation for support [24]. A
prospective cohort study of following 1590 COVID-19 pa-
tients in China demonstrated that of the 18 patients with can-
cer, lung cancer was the most frequently incurred malignancy.
Moreover, in this cohort, history of cancer was associatedwith
a higher risk of severe events (ICU admission requiring ven-
tilation or death) and faster progression to severe events (me-
dian time for cancer patients 13 days vs. 43 days for non-
cancer patients). Those with a history of chemotherapy or
surgery in the past month had a higher risk for severe events
even when adjusted for other risk factors including age (OR
5.34, 95% CI 1.80–16.18; p < 0.005). Of the 18 described in
the Wuhan group, roughly 10% received chemotherapy and
7.1% targeted therapy. However, age alone was also an inde-
pendent risk factor for severe events in the cancer group of
patients. Those with history of lung cancer versus other cancer
types did not predict a more severe outcome [42].
Another study from China evaluating all cancer patients
admitted to Zhongnan Hospital of Wuhan University deter-
mined that cancer patients had a 0.79% infection rate com-
pared with the overall city’s 0.37% infection rate. A total of 12
patients were affected, 58.3% had non-small cell lung carci-
noma (NSCLC) with approximately 41.7% were undergoing
treatment with chemotherapy and resulting mortality rate as of
March 10, 2020, being 25%. Additionally, NSCLC patients
that were greater than age 60 had a higher incidence of
COVID-19 compared with younger patients with NSCLC
[43•]. These findings are further corroborated by a study that
examined all 28 cancer patients admitted to 3 hospitals in
China. Lung cancer was the most common cancer type among
these patients (25%). Diabetes (14.3%) and chronic cardiovas-
cular and cerebrovascular disease (14.3%) were the most com-
mon comorbidities listed. Clinical factors that significantly
predicted worse outcomes in this group of patients included
age, patchy consolidation on imaging, and receipt of anti-
tumor treatment in the last 14 days [44]. These studies suggest
that patients with cancer are at higher risk for COVID-19, and
those with older age and cancer are at an even higher risk for
poor outcomes. Lung cancer has been reported to be more
common in these studies, but the total sample size of cancer
patients remains too low to draw any meaningful conclusions
on which malignancy may be most associated with severity of
COVID-19 infections. Lastly, although having recent anti-
cancer treatment increases the risk for severe outcomes, it is
unclear which anti-cancer agents are associated with higher
risk for acquiring COVID-19 infection, severity of infection,
and/or mortality. Table 1 demonstrates a literature review of
studies published until April 26, 2020 that identify the preva-
lence of cancer among COVID-19 infected patients.
Although no formal studies have assessed the direct impact
of COVID-19 on cardio-oncology patients, a study has shown
that both CVD patients and cancer patients do have an in-
creased risk for cardiac injury which in of itself is an indepen-
dent predictor of mortality [28]. Additionally, since the data
suggests that CVD and cancer are potentially independent risk
factors for virus acquisition and severe outcomes, it is reason-
able to assume that if patients have both risk factors, then they
may posit higher cumulative risk. There is also concern that
cancer treatments may induce disease states such as hyperten-
sion and cardiovascular disease—both frequently associated
risk factors for worse outcomes in COVID-19 patients [19•].
An example of such a clinical scenario could involve metasta-
tic renal carcinoma patients who develop hypertension from
anti-VEGF tyrosine kinase therapy, or cardiomyopathy from
anti-HER2, and anthracycline therapy of breast cancer [45,
46]. However, the definition of “cardiovascular disease” that
patients have been classified with in these studies is not al-
ways clearly delineated; thus, risk stratification of these pa-
tients in regard to COVID-19 risk requires more refined in-
vestigation and long-term follow-up regarding outcomes.
The elevated risk that cancer patients face during the
COVID-19 pandemic poses many challenges. Some of these
include providing ongoing cancer treatments especially if pa-
tients are undergoing curative therapy, enrolling patients into
experimental drug trials, continuing close cardiotoxicity sur-
veillance, and providing treatments to patients who have an
optimal window of adequate functional status [47, 48]. Given
concerns for hospital-acquired COVID-19 infections, this ad-
ditional risk factor can impact continuation of therapy or
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initiation of regimens for aggressive malignancy that require
hospitalization for closer monitoring [43, 47, 48]. Moreover,
patients that may rely on drugs or stem cell donations for
treatment may necessitate access to unique global sources
and are rendered at a disadvantage due to travel restrictions
and quarantine policies [49]. In response to these climactic
changes, The National Comprehensive Cancer Network and
National Cancer Institute have provided guidance to providers
on providing care to oncology patients, resource allocation,
and managing drug trials [50].
Healthcare-Related Exposure
As referenced above, a unique source of transmission in the
cardio-oncology population is healthcare exposure.
Healthcare-related exposure is being given greater importance
as an attributable vector. Past experience with SARS-CoV
demonstrated that the virus can be transmitted via aerosolizing
procedures, such as endotracheal intubation, placing anesthe-
siologists at great risk for acquiring the infection [51, 52].
During the outbreak of COVID-19, implementation of infec-
tion control and establishment of safe personal protective
equipment (PPE) remained and remains key. Intense aerosol-
izing procedures, such as emergent intubations, cardiopulmo-
nary resuscitation, or bronchoscopies, should require stringent
PPE to maintain adequate protection. Despite attempting to
roll out these precautions, review of the WHO-China Joint
Mission on COVID confirmed that nearly 3387 healthcare
workers tested positive for COVID-19 infection, resulting in
22 deaths [53]. While initial understanding of the pathogen
remained poor, long-time exposure to large-scale infected pa-
tients directly increased the risk of infection for healthcare
workers and risk of being an asymptomatic carrier [54].
Fatigue, lack of available healthcare workers, limited re-
sources, and intensity of response led to several healthcare
workers succumbing to infection. Though unsettling, it is dou-
bly important to place value on healthcare-related exposure as
an established risk factor when dealing with cancer patients
with pre-existing risk factors.
Coronavirus Structure and Foundation
for Treatment Strategies
Coronaviruses are a large collection of single-stranded
enveloped, non-segmented positive-sense RNA viruses that
fall within the family of Coronaviridae and the order
nidovirales [55]. Six specific coronaviruses have been identi-
fied as human-susceptible, among which alpha and beta sub-
sets demonstrated lower pathogenicity and caused milder re-
spiratory symptoms respectively. Genomic analysis of SARS-
COV-2 showcased 96.2% shared sequencing with bat CoVTa
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RATG13, thus positing that the bat variant served as the nat-
ural host of the virus [4]. However, the severe acute syn-
dromes belong to the B-genus, with envelope-anchored spike
protein mediating viral entry into host cells by first binding to
a host receptor and subsequently fusing membranes [56]. The
COVID-19 infection has a well-defined capsular structure
with 14 binding residues, with 8 conserved from prior
SARS-CoV infections. The viral genome contains several
open reading frames, with majority of the viral RNA-
encoding non-structural proteins (NSPs) that play a role in
the pathogenesis of disease. Recent research studies focusing
on NSP2 and NSP3 demonstrated an in vivo role that these
subunits may play in infectious capability and differentiation
of COVID-19 [57].
Mechanistically, COVID-19 is found to be linked to
Angiotensin-Converting Enzyme 2, a membrane-bound ami-
nopeptidase highly expressed in lung, intestinal, and heart
tissue. Beyond being implicated in hypertension and diabetes,
ACE-2 further functions as a receptor for coronaviruses [58•].
COVID-19 translocates into lung parenchyma via damaging
epithelial cells, resulting in respiratory symptoms, with symp-
tom severity worsening in patients with cardiovascular dis-
ease. ACE2 secretion is noted to be elevated in CVD patients
due to increased reliance on angiotensin-receptor blockers for
management of hypertension. At the receptor level, the
receptor-binding domain of SARS-CoV spike protein specif-
ically recognizes ACE2, which contributes to both cross-
species and human-to-human transmission [59, 60].
Documented variability is demonstrated between various
strains of SARS-CoV in terms of binding affinity and viral
attachment, which is preserved across both humans and ani-
mal models of disease transmission [61]. The preserved do-
mains across MERS/SARS may contribute to the heightened
inflammatory response and cytokine milieu that leads to se-
vere pneumonia [62].
On a molecular level, specific associations and descriptive
characteristics of the patients identified cytokine abnormalities
in ICU-level patients versus non-ICU–level admissions.
Compared with non-ICU patients, ICU patients had higher
plasma levels of IL-2, IL-7, IL-10, G-CSF, IP-10, MCP-1,
MIP-1A, and TNF-a [63•]. Though this cytokine thumbprint
is being linked to COVID-19 infection, ARDS similarly
showcases elevations in inflammatory markers, questioning
origin and role of virally mediated hyperinflammation [64].
Potential Overlapping Mechanisms
in COVID-19 and Cardiovascular Disease
and Anti-cancer Treatments
Multiple treatments are being assessed in various trials includ-
ing antivirals, anti-inflammatories, immunotherapies, and car-
diovascular medications for the treatment of COVID-19.
Although some these therapies have potential to provide ben-
efit, there are numerous potential cardiac toxicities and drug-
drug interactions that may be harmful to cardio-oncology pa-
tients, which is critically relevant since a high percentage of
COVID-19 patients have cardiovascular comorbidities
[65–68]. An appraisal of these agents and their potential
cardiotoxicities—of which there is no current proven efficacy
at this time—is beyond the scope of this review. However,
some agents are actively used in the treatment of cardiovas-
cular disease and/or cancer-related conditions, and the unique
disease states of the cardio-oncology population may yield
insights into the mechanisms of COVID-19 pathophysiology.
For instance, the idea of using medications that have al-
ready been well-studied and target host responses by boosting
host immunity was in discussion during prior significant out-
breaks and epidemics including Ebola and influenza [69, 70].
ACE inhibitors (ACEI), angiotensin-receptor blockers (ARB),
and statins are of particular importance during this current
pandemic.
There has been a theoretical uncertainty in regard to the
safety of ACEI/ARB use in patients with COVID-19 based
on the ACE2 viral entry mechanism [71, 72]. The virus gains
cellular entry by attaching to the ACE2 receptor [72]. ACE2
expression and activity have shown to be increased in by
ACEI/ARB use [73]. Although there is theoretical risk that
ACE2 upregulation may increase the susceptibility of infec-
tion, other conflicting evidence indicates that upregulation of
ACE2 in fact has a more protective effect. Studies in mouse
models have shown that ACE2 is protective against acute lung
injury and blocking the renin-angiotensin-aldosterone system
pathway decreases lung failure [74, 75]. Based on the review
of the literature to date, the Heart Failure Society of America
recommends continuation of ACEI/ARB use for patients that
are prescribed them for heart failure, hypertension, and ische-
mic disease [76••]. Abrupt discontinuation of medications is
not recommended and can worsen clinical stability especially
in patients with existing cardiovascular conditions [71].
Additionally, statins have long been shown to have anti-
inflammatory properties through multiple studies. For in-
stance, simvastatin has been shown to decrease pulmonary
inflammation in human subjects [77]. Although the benefits
for cardiovascular patients have been numerous from a lipid
lower standpoint, it is important to note that the ability of
statins to decrease inflammation also improves mortality
[78]. A retrospective analysis of patients from the Veterans
Administration showed that statin use, ACEI use, or ARB
use each independently improved 30 day mortality of patients
> 65 years old who were hospitalized for pneumonia [79].
However, in the era of the COVID-19 pandemic, studies are
needed to evaluate its role in COVID-19–related illness.
Although cancer patients have been considered immuno-
suppressed as a result of their underlying malignancy and
cytoreduction therapies, patients that undergo immunotherapy
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including immune checkpoint inhibitors (ICIs) or CAR-T cell
therapy may have different immuno-physiology that responds
to COVID-19 differently [80]. Anti-PD-1/PD-L1 and anti-
CTLA-4 ICIs have been approved by the FDA for use in a
variety of cancers. These drugs primarily work by enhancing a
patient’s immune response to tumors through inhibiting neg-
ative regulators of T cell function [81]. CAR-T cell therapy
involves reprogramming a patient’s own T cells to directly
target their specific tumor [82].
An adverse effect that can occur with either anti-PD-1 ther-
apy or CAR-T cell therapy involves cytokine release syn-
drome (CRS) which is similar to the cytokine storm phenom-
enon that occurs in patients with severe COVID-19 [80, 82,
83]. CRS occurs as a result of hyperimmune activation in
response to tumor death, whereas cytokine storm in COVID-
19 patients occurs as a result of T cell hyperactivation from
immune dysregulation [80, 84]. Similar markers are elevated
in both phenomena, including IL-6, TNF-alpha, and IFN-λ, of
which IL-6 has also been shown to be a mortality predictor in
COVID-19 patients [27, 64, 80, 84]. COVID-19 patients that
develop cytokine storm syndrome are at risk of developing
ARDS and multi-organ failure [84, 85]. Immunosuppression
with tocilizumab, an IL-6 inhibitor, is used to treat CRS asso-
ciated with CAR-T cell therapy [80, 86]. Additionally, toci-
lizumab immunosuppression is used to treat immune-related
adverse events (irAEs) from PD-1 inhibitors that are refractory
to steroids; irAEs also occur as a result of hyperimmune acti-
vation [80, 87]. Moreover, the cytokine storm observed with
COVID-19 has also been noted to be similar to that of sec-
ondary hemophagocytic lymphohistiocytosis (HLH) which is
also treated with immunosuppression [64].
Current trials are underway with using tocilizumab and
sarilumab (another IL-6 inhibitor) to treat COVID-19 patients
[88–90]. Although immunotherapy may be thought to rein-
state a cancer patient’s immunocompetence, there is potential
for synergy from CRS and the COVID-19 cytokine storm
pathogenesis which can further worsen a patient’s mortality
risk. Further unfavorable synergy between ICI immune-
related adverse events (irAEs) can also be seen potentially
between the pneumonitis that ICIs can cause and the lung
involvement with COVID-19 [80]. Pneumonitis occurs in <
10% of patients being treated with anti-CTLA-4 and anti-PD-
1 ICIs and is potentially life-threatening [81]. Therefore, if
combined with lung injury from COVID-19, there is a theo-
retical potential for poor outcomes.
There are potential cancer treatments that may counteract
the pathogenesis of COVID-19, such as CCR5 treatments and
tyrosine kinase inhibitors (TKIs) [91–93]. The CCR5 receptor
is a G protein–coupled receptor selectively expressed on mac-
rophages, T cells, eosinophils, dendritic cells, and microglia
and is implicated in chemokine-mediated signaling [94]. This
receptor has historically been targeted for HIV antiviral thera-
py, in the setting of disrupting viral entry, specifically through
small molecule inhibition with maraviroc and vicriviroc, and
monoclonal antibody treatment with leronlimab [95].
Moreover, multiple cancers have been shown to overexpress
CCR5 which has been linked to a cancer’s metastatic poten-
tial. CCR5 therapies are currently being studied in metastatic
colorectal and breast cancers [91, 94]. Due to its immune
system restorative properties, leronlimab is being investigated
for compassionate use in the treatment of COVID-19 patients
[96, 97]. Studies examining receptor blockade in leronlimab
preliminarily have shown decreases in IL-6, restoration of
CD4/CD8 ratios, and reduction in overall COVID-19 viremia
[98]. These collective findings suggest possible therapeutic
role in establishing immune reconstitution in patients that
are critically ill and may provide dual benefit in patients with
shared cancer diagnoses.
TKIs like sunitinib and erlotinib that specifically inhibit
AAK1, a protein regulator that allows passage of the virus
into cells, have theorized utility [92]. Sunitinib is an anti-
vascular endothelial growth factor (VEGF) TKI which is used
in first-line for treatment of advanced renal cell carcinoma
[99]. Erlotinib is an anti-epidermal growth factor receptor
(EGFR) TKI which is used in first-line treatment for metasta-
tic EGFR-mutant non-small cell lung cancer [100]. Both these
TKIs have shown to reduce the infectivity of Dengue and
Ebola through in vivo studies with murine models which
showed decreased viremia and mortality with treatments.
Moreover, in vitro studies in cultured cells and hepatitis C in
this same study showed that use of these TKIs reduced intra-
cellular trafficking and inhibited viral entry [101]. However,
the high doses required to achieve this effect may potentially
exhibit harm to patients [92, 93]. Regardless, there is potential
for cancer patients receiving these therapies to achieve dual
benefit as referenced before, but warrant further investigation.
Further studies are warranted in tracking the outcomes of can-
cer patients with COVID-19 and the type of treatments they
received.
Role for Anticoagulation in COVID-19
Patients with underlying hypertension, diabetes, and cancer
are at higher risk for developing thrombotic events.
Coagulopathy in coronavirus infection is now associated with
high mortality and manifests with high D-dimer elevations
[102]. Lung inflammation and impaired pulmonary gas ex-
change contributes to cytokine storm, which leads to spike
in D-dimer and pro-inflammatory response, with impaired en-
dothelial function. Tissue factor (TF), expressed by tumor
cells, contributes to thrombosis, metastasis, tumor growth,
and tumor angiogenesis, leading to release of pro-coagulant
microparticles into the circulation and triggering thromboem-
bolism in patients with cancer [103]. TF on circulating tumor
cells leads to coating of cells with fibrin that traps them within
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microvasculature, thereby contributing to worsening endothe-
lial dysfunction [104]. In patients with pre-existing cancer
diagnoses, shared COVID infection as well as hypoxia places
them at even greater risk of developing and incurring throm-
botic events [105]. Early heparin initiation is posited to delay
the spike in inflammatory biomarkers and may reduce contri-
butions to pro-coagulopathic state [106]. A retrospective study
from China examined 449 patients classified as having severe
COVID-19 infection, of which 272 had one or more chronic
underlying diseases, such as hypertension and heart disease.
Patients were assigned to receive various forms of heparin,
with those treated with heparin having a lower mortality rate
(40% vs. 64.2%, p = 0.029) [107]. Data regarding initiation
and choice of anticoagulation remains limited, and further
randomized clinical trials are necessary to determine prophy-
lactic and treatment strategies for cardio-oncology patients
infected with COVID-19, as they represent a population with
elevated theoretical risk for suffering from thromboembolic
events.
Care of the Cardio-Oncology Patient
in the COVID-19 Era
The COVID-19 pandemic has added a significant layer and
complexity of how patient care is being delivered due to con-
cerns of bidirectional transmission, with no protective algo-
rithm widely in place to dictate ongoing management of can-
cer patients [108••]. Initiating cancer treatments, such as
targeted immunotherapies and chemotherapy, require special
consideration in the COVID-19 era. As previously described,
compromised immune systems render patients with cancer at
higher risk for acquiring COVID-19 infection and the sequel-
ae that may ensue. Cancer treatment centers and cardio-
oncologists must now consider not only the patient but also
the integral healthcare workers who are regularly interfacing
with high-risk exposures. Devising strategies to ensure robust
testing services and clearance mechanisms to protect patient
and healthcare personnel is one of many methods now
employed to continue ongoing treatments [48, 109, 110].
Though there are no clear evidence-based modifications in
systems of care to reduce transmission risk while balancing
high-standard cardio-oncology care, various strategies are
proposed (Table 2). Life-prolonging surgeries and procedures
can slowly be pursued and continued, although the risks of
delaying any such advanced treatments—including bone mar-
row transplantation and chimeric antigen receptor treatment—
need to be weighed carefully. COVID-19 screening and test-
ing prior to these surgeries/procedures, while not infallible,
should be considered if available due to rising concern for
asymptomatic carriers. Following completing anti-cancer
treatments, patients may additionally benefit from receiving
immune system restorative treatments, such as filgastrim.
Additionally, the transition to telemedicine to conduct in-
terval cardiovascular and oncologic appointments can poten-
tially protect patients from unnecessarily harmful nosocomial
exposures [111, 112]. Certain chronic conditions (i.e., hyper-
tension, stable/compensated congestive heart failure) may not
necessarily require a face-to-face visit, whereas highly symp-
tomatic patients should still be seen in the cardio-oncology
clinic, preferably on the same day as their cancer outpatient
visits. Deferring primary prevention assessments, for exam-
ple, cholesterol monitoring, unless otherwise indicated can
augment protective mechanisms in place. Cardiovascular-
related blood draws, if necessary, should be coincided with
cancer-related treatments.
In addition, the specter of cardiotoxicity related to certain
cancer treatments also requires a reexamination of risk and ben-
efit with respect to frequent cardiac monitoring due to previously
mentioned concerns. Peri-chemotherapeutic events and develop-
ment of cardiomyopathy, ischemia, and life-threatening arrhyth-
mias are further worsened by simultaneous COVID infection.
Reducing reliance on frequent cardiac imaging in otherwise
asymptomatic patients and providing in-mail ambulatory rhythm
monitors for patients symptomatic with possible arrhythmias will
further assist in mitigating exposure risk. Limited cardiac-
imaging protocols (i.e., focused just on ventricular function
and/or pericardial disease) if necessary for symptomatic patients
or those necessitating cardiotoxicity surveillance can also be de-
vised to reduce exposure time in the healthcare setting. In addi-
tion, for patients at low risk of cardiotoxicity and/or with prior
serial-documented normal cardiac function, it can be considered
to defer serial cardiac imaging in certain treatments (i.e., anti-
HER2 without anthracyclines, BRAF-MEK treatments), in mul-
tidisciplinary discussions with oncology if the patient is asymp-
tomatic [113].
Conclusion
The COVID-19 pandemic has caused an unprecedented glob-
al impact on healthcare delivery, and its trajectory continues to
remain unclear. Vulnerable patient populations include those
with cardiovascular disease and cancer, and the cardio-
oncology patient, having possessed both these risk factors,
may unfortunately be at significantly increased risk of
experiencing worse outcomes related to COVID-19 infection.
As of this writing, there are no known studies focusing on the
cardio-oncology population, and there remain many opportu-
nities to not only study the epidemiology of this unique but
also significant group of patients. Clinical trials are ongoing,
but rigorous, randomized high-quality science is warranted to
study the efficacy of previously mentioned treatments; they
also may potentially reveal critical mechanistic insights into
COVID-19’s pathophysiology, which overlap with cardiovas-
cular and cancer disease states [114]. In addition, the abrupt
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and possibly permanent alteration of cardiovascular and can-
cer systems of care—with the dramatic rise of telemedicine
and other changes—to mitigate transmission risk in the
COVID-19 era also warrants close study to evaluate clinical
outcomes. Much remains unknown about how the pandemic
will affect the cardio-oncology population and how they will
be cared for, but what is certain is that ongoing, close multi-
disciplinary care and communication between the cardiac and
cancer care providers of these patients remains more critical
than ever in order to guarantee the best care possible.
Table 2 Proposed special considerations of the cardio-oncology patient during the COVID-19 pandemic
Cardio-oncology aspect of care Theoretical areas of concern Proposed Strategies to Mitigate COVID-19
Exposure
Initiating/ongoing cancer treatments (i.e.,
chemotherapy, targeted therapies,
immunotherapy, BMT, CAR-T), and
timing of oncologic-related surgery
• Compromised immune systems induced by cancer
treatments may make patient more susceptible to
COVID-19
• Cancer treatments may require healthcare
facility/inpatient stay exposing patient to
asymptomatic carriers (i.e., HCW)
• Delaying of potential critical, life-prolonging
surgery as it may be deemed as “elective”
• Ensuring COVID-19 testing adequacy by
healthcare providers
• Implementation of universal PPE and social
distancing during cancer treatments in
outpatient/inpatient settings, and with family
members/caretakers
• Weighing risk-benefit of postponing/delaying
timing of cancer treatments/surgery to minimize
exposure to inpatient healthcare setting
• Preoperative/procedural screening and testing for
COVID-19
• Telemedicine for routine follow-up
cardio-oncology/oncology visits unless clinically
symptomatic
• Research efforts investigating earlier utilization of
immune system restorative measures post
anti-tumor therapy
• Consideration of delaying myeloablative therapies
and immunotherapies for patients in clinical
remission if possible
• Consideration of minimizing surveillance/staging
imaging during and after treatments
Cardiotoxicity experienced during cancer
treatments (i.e., cardiomyopathy,
arrhythmias, and ischemic events)
• Further delay of cancer treatments and
cardio-oncology evaluation because of
COVID-19 may increase cardiac and
cancer-related comorbidity and mortality
• Cardiac imaging and testing may cause further
exposure to asymptomatic carriers
• Inpatient admission and evaluation as clinically
indicated for severe symptoms
• Telemedicine for patients who are asymptomatic or
minimally symptomatic, or CVD risk factor
modification (i.e., visits for HTN and/or
dyslipidemia)
• Preemptive aggressive treatment for suspected
symptoms related to CAD, arrhythmias, or CHF
and deferring of imaging unless clinically
necessary
• Mail ambulatory rhythm monitors to home to
evaluate suspected/known arrhythmias
Cardiotoxicity surveillance in cancer
patients during and after treatment
• Some cancer treatments (i.e., anti-HER2,
BRAF-MEK treatments, clinical trials) require
frequent surveillance of cardiac function (i.e.,
every 3 months)
• Patients with known cardiotoxicity, or with known
treatments that can cause long-term cardiotoxicity
(i.e., anthracyclines, radiation) may not get timely
surveillance imaging
• Minimize cardiac imaging to patients who are
symptomatic
• Multidisciplinary discussion with
hematologist/oncologist about reducing
frequency of cardiotoxicity screening, especially
if prior serial testing unremarkable
• Limited imaging protocols to evaluate LVEF to
minimize acquisition time
• Defer primary prevention assessment (i.e.,
dyslipidemia management) unless critical to care
of patient
• Telemedicine visits for patients who do not require
face-to-face assessment for medical issues (i.e.,
blood pressure/lipid management/stable CHF)
• Defer asymptomatic long-term cancer survivor
surveillance (i.e., assessment of ventricular and
valvular function) if no symptoms
BMT bone marrow transplantation, CAR-T chimeric antigen receptor therapy, HCW healthcare workers, PPE personal protective equipment, CVD
cardiovascular disease, CAD coronary artery disease, CHF congestive heart failure, LVEF left ventricular ejection fraction
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